The emergence, surge and subsequent wave of the SARS-CoV-2 pandemic in New York metropolitan area: The view from a major region-wide urgent care provider.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
12 Apr 2021
12 Apr 2021
Historique:
entrez:
21
4
2021
pubmed:
22
4
2021
medline:
22
4
2021
Statut:
epublish
Résumé
Describing SARS-CoV-2 testing and positivity trends among urgent care users is crucial for understanding the trajectory of the pandemic. To describe demographic and clinical characteristics, positivity rates, and repeat testing patterns among patients tested for SARS-CoV-2 at CityMD, an urgent care provider in the New York City metropolitan area. Retrospective study of all persons testing for SARS-CoV-2 between March 1, 2020 and January 8, 2021 at 115 CityMD locations in the New York metropolitan area. Individuals receiving a SARS-CoV-2 diagnostic or serologic test. Test and individual level SARS-CoV-2 positivity by PCR, rapid antigen, or serologic tests. During the study period, 3.4 million COVID tests were performed on 1.8 million individuals. In New York City, CityMD diagnosed 268,298 individuals, including 17% of all reported cases. Testing levels were higher among 20-29 year olds, non-Hispanic Whites, and females compared with other groups. About 24.8% (n=464,902) were repeat testers. Test positivity was higher in non-Hispanic Black (6.4%), Hispanic (8.0%), and Native American (8.0%) patients compared to non-Hispanic White (5.4%) patients. Overall seropositivity was estimated to be 21.7% (95% Confidence Interval [CI]: 21.6-21.8) and was highest among 10-14 year olds (27.3%). Seropositivity was also high among non-Hispanic Black (24.5%) and Hispanic (30.6%) testers, and residents of the Bronx (31.3%) and Queens (30.5%). Using PCR as the gold standard, SARS-CoV-2 rapid tests had a false positive rate of 5.4% (95%CI 5.3-5.5). Urgent care centers can provide broad access to critical evaluation, diagnostic testing and treatment of a substantial number of ambulatory patients during pandemics, especially in population-dense, urban epicenters.
Sections du résumé
BACKGROUND
BACKGROUND
Describing SARS-CoV-2 testing and positivity trends among urgent care users is crucial for understanding the trajectory of the pandemic.
OBJECTIVE
OBJECTIVE
To describe demographic and clinical characteristics, positivity rates, and repeat testing patterns among patients tested for SARS-CoV-2 at CityMD, an urgent care provider in the New York City metropolitan area.
DESIGN
METHODS
Retrospective study of all persons testing for SARS-CoV-2 between March 1, 2020 and January 8, 2021 at 115 CityMD locations in the New York metropolitan area.
PATIENTS
METHODS
Individuals receiving a SARS-CoV-2 diagnostic or serologic test.
MEASUREMENTS
METHODS
Test and individual level SARS-CoV-2 positivity by PCR, rapid antigen, or serologic tests.
RESULTS
RESULTS
During the study period, 3.4 million COVID tests were performed on 1.8 million individuals. In New York City, CityMD diagnosed 268,298 individuals, including 17% of all reported cases. Testing levels were higher among 20-29 year olds, non-Hispanic Whites, and females compared with other groups. About 24.8% (n=464,902) were repeat testers. Test positivity was higher in non-Hispanic Black (6.4%), Hispanic (8.0%), and Native American (8.0%) patients compared to non-Hispanic White (5.4%) patients. Overall seropositivity was estimated to be 21.7% (95% Confidence Interval [CI]: 21.6-21.8) and was highest among 10-14 year olds (27.3%). Seropositivity was also high among non-Hispanic Black (24.5%) and Hispanic (30.6%) testers, and residents of the Bronx (31.3%) and Queens (30.5%). Using PCR as the gold standard, SARS-CoV-2 rapid tests had a false positive rate of 5.4% (95%CI 5.3-5.5).
CONCLUSION
CONCLUSIONS
Urgent care centers can provide broad access to critical evaluation, diagnostic testing and treatment of a substantial number of ambulatory patients during pandemics, especially in population-dense, urban epicenters.
Identifiants
pubmed: 33880480
doi: 10.1101/2021.04.06.21255009
pmc: PMC8057248
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : UH3 AI133675
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
PLoS Med. 2020 Sep 22;17(9):e1003379
pubmed: 32960880
Am J Prev Med. 2020 Sep;59(3):326-332
pubmed: 32703702
Science. 2021 Jan 8;371(6525):126-127
pubmed: 33414210
JMIR Public Health Surveill. 2021 Dec 30;7(12):e32846
pubmed: 34793320
Clin Infect Dis. 2020 Dec 3;71(9):2469-2479
pubmed: 32392337
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1725-1729
pubmed: 33211680
J Urban Health. 2020 Aug;97(4):461-470
pubmed: 32691212
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
JMIR Public Health Surveill. 2020 Dec 31;6(4):e25546
pubmed: 33315584
N Engl J Med. 2021 Feb 4;384(5):474-480
pubmed: 33406325
World Med Health Policy. 2020 Sep;12(3):311-327
pubmed: 32837779